Can-Fite BioPharma Ltd. (CANF) Form 6-K — Jul 14, 2026

$CANFForm 6-KFiled Jul 14, 2026, 7:12 AM ET0001213900-26-077775Original filing

Can-Fite BioPharma announced that the Australian Patent Office has allowed a patent application for its drug candidate Namodenoson covering the treatment of advanced metastatic cancer. This allowance strengthens the company's global intellectual property portfolio, specifically supporting the ongoing Phase 3 study for liver cancer and the planned Phase 2b study for pancreatic cancer.

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.